Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD) episode artwork

EPISODE · Mar 13, 2025 · 7 MIN

Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)

from BiotechTV - News · host BiotechTV

Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.

Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.

NOW PLAYING

Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)

0:00 7:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 7 minutes long.

When was this BiotechTV - News episode published?

This episode was published on March 13, 2025.

What is this episode about?

Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!